Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 8/20 | 0.93 |
| ▸ | MERTK | Q12866 | 13/20 | 0.81 |
| ▸ | AXL | P30530 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398147 | 0.96 | TYRO3 (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398176 | 0.90 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398128 | 0.90 | TYRO3 (1.00) | TYRO3MERTKAXL | |
| SCHEMBL23965835 | 0.90 | TYRO3 (0.87) | TYRO3MERTK | |
| SCHEMBL19398177 | 0.89 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL24371883 | 0.89 | TYRO3 (0.85) | TYRO3MERTKAXL | |
| SCHEMBL19398182 | 0.88 | MERTK (1.00) | TYRO3MERTKAXL | |
| SCHEMBL19398178 | 0.88 | MERTK (0.83) | TYRO3MERTKAXL | |
| SCHEMBL19377724 | 0.86 | TYRO3 (1.00) | TYRO3MERTKAXL | |
| SCHEMBL30367450 | 0.86 | TYRO3 (0.81) | TYRO3MERTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORPORATION | 2024-12-26 | — | — | US | claimed |
| CN-113164398-B | Formulations of AXL/MER inhibitors | 因赛特公司 | 2023-11-03 | — | — | CN | claimed |
| US-11241438-B2 | Formulations of an AXL/MER inhibitor | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | INCYTE CORPORATION | 2024-12-26 | — | — | US | disclosed |
| CN-117771250-A | Formulations of AXL/MER inhibitors | 因赛特公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113164398-B | Formulations of AXL/MER inhibitors | 因赛特公司 | 2023-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241438-B2 | Formulations of an AXL/MER inhibitor | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
| US-12318389-B2 | Formulations of an AXL/MER inhibitor | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
| US-20240423991-A1 | FORMULATIONS OF AN AXL/MER INHIBITOR | AXL, MERTK, RET | TYRO3 4/4885MERTK 2/4885AXL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.